Tags

Type your tag names separated by a space and hit enter

Invasive intraductal papillary-mucinous neoplasm of the pancreas: comparison with pancreatic ductal adenocarcinoma.
J Surg Oncol. 2009 Jul 01; 100(1):13-8.JS

Abstract

BACKGROUND AND OBJECTIVES

The aim of this study was to clarify the clinicopathological differences between patients with invasive intraductal papillary-mucinous neoplasm (IPMN) of the pancreas and pancreatic ductal adenocarcinoma.

METHODS

The medical records of 16 patients with invasive IPMN and 106 patients with pancreatic ductal adenocarcinoma, who underwent surgical resection, were retrospectively reviewed, and the clinicopathological factors and survival were compared between the two groups.

RESULTS

The presence of retroperitoneal tissue invasion, portal or splenic vein invasion, nodal involvement, and positive surgical margins were significantly lower in patients with invasive IPMN than in those with ductal adenocarcinoma (P < 0.05). The actuarial 5-year overall survival rates in patients with invasive IPMN and ductal carcinoma were 40% and 18%, respectively (P = 0.008). However, the actuarial 5-year survival rate of patients with invasive IPMN was only 27% for UICC stage II disease, although this was significantly higher than that of patients with UICC stage II ductal adenocarcinoma (P = 0.049).

CONCLUSIONS

Invasive IPMN has a favorable prognosis compared with pancreatic ductal adenocarcinoma that is likely due to the less aggressive nature of the disease. However, the prognosis for cases of advanced invasive IPMN is not always favorable despite complete tumor resection.

Authors+Show Affiliations

Department of Surgery, Division of Clinical Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan. mura777@hiroshima-u.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

19384908

Citation

Murakami, Yoshiaki, et al. "Invasive Intraductal Papillary-mucinous Neoplasm of the Pancreas: Comparison With Pancreatic Ductal Adenocarcinoma." Journal of Surgical Oncology, vol. 100, no. 1, 2009, pp. 13-8.
Murakami Y, Uemura K, Sudo T, et al. Invasive intraductal papillary-mucinous neoplasm of the pancreas: comparison with pancreatic ductal adenocarcinoma. J Surg Oncol. 2009;100(1):13-8.
Murakami, Y., Uemura, K., Sudo, T., Hayashidani, Y., Hashimoto, Y., Nakashima, A., & Sueda, T. (2009). Invasive intraductal papillary-mucinous neoplasm of the pancreas: comparison with pancreatic ductal adenocarcinoma. Journal of Surgical Oncology, 100(1), 13-8. https://doi.org/10.1002/jso.21290
Murakami Y, et al. Invasive Intraductal Papillary-mucinous Neoplasm of the Pancreas: Comparison With Pancreatic Ductal Adenocarcinoma. J Surg Oncol. 2009 Jul 1;100(1):13-8. PubMed PMID: 19384908.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Invasive intraductal papillary-mucinous neoplasm of the pancreas: comparison with pancreatic ductal adenocarcinoma. AU - Murakami,Yoshiaki, AU - Uemura,Kenichiro, AU - Sudo,Takeshi, AU - Hayashidani,Yasuo, AU - Hashimoto,Yasushi, AU - Nakashima,Akira, AU - Sueda,Taijiro, PY - 2009/4/23/entrez PY - 2009/4/23/pubmed PY - 2009/7/1/medline SP - 13 EP - 8 JF - Journal of surgical oncology JO - J Surg Oncol VL - 100 IS - 1 N2 - BACKGROUND AND OBJECTIVES: The aim of this study was to clarify the clinicopathological differences between patients with invasive intraductal papillary-mucinous neoplasm (IPMN) of the pancreas and pancreatic ductal adenocarcinoma. METHODS: The medical records of 16 patients with invasive IPMN and 106 patients with pancreatic ductal adenocarcinoma, who underwent surgical resection, were retrospectively reviewed, and the clinicopathological factors and survival were compared between the two groups. RESULTS: The presence of retroperitoneal tissue invasion, portal or splenic vein invasion, nodal involvement, and positive surgical margins were significantly lower in patients with invasive IPMN than in those with ductal adenocarcinoma (P < 0.05). The actuarial 5-year overall survival rates in patients with invasive IPMN and ductal carcinoma were 40% and 18%, respectively (P = 0.008). However, the actuarial 5-year survival rate of patients with invasive IPMN was only 27% for UICC stage II disease, although this was significantly higher than that of patients with UICC stage II ductal adenocarcinoma (P = 0.049). CONCLUSIONS: Invasive IPMN has a favorable prognosis compared with pancreatic ductal adenocarcinoma that is likely due to the less aggressive nature of the disease. However, the prognosis for cases of advanced invasive IPMN is not always favorable despite complete tumor resection. SN - 1096-9098 UR - https://www.unboundmedicine.com/medline/citation/19384908/Invasive_intraductal_papillary_mucinous_neoplasm_of_the_pancreas:_comparison_with_pancreatic_ductal_adenocarcinoma_ DB - PRIME DP - Unbound Medicine ER -